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Canine leishmaniosis (CanL) caused by Leishmania infantum is a zoonotic disease of
global concern. Antileishmanial drug therapies commonly used to treat sick dogs improve
their clinical condition, although when discontinued relapses can occur. Thus, the current
study aims to evaluate the effect of CanL treatments in peripheral blood, lymph node,
and bone marrow cytokine profile associated with clinical recovery. Two groups of six
dogs diagnosed with CanL were treated with miltefosine combined with allopurinol and
meglumine antimoniate combined with allopurinol (MT+A and MG+A), respectively. At
diagnosis and after treatment, during a 3-month follow-up, clinical signs, hematological
and biochemical parameters, urinalysis results and antileishmanial antibody titers were
registered. Furthermore, peripheral blood, popliteal lymph node, and bone marrow
samples were collected to assess the gene expression of IL-2, IL-4, IL-5, IL-10, IL-12,
TNF-α, TGF-β, and IFN-γ by qPCR. In parallel, were also evaluated samples obtained
from five healthy dogs. Both treatment protocols promoted the remission of clinical signs
as well as normalization of hematological and biochemical parameters and urinalysis
values. Antileishmanial antibodies returned to non-significant titers in all dogs. Sick dogs
showed a generalized upregulation of IFN-γ and downregulation of IL-2, IL-4, and TGF-β,
while gene expression of IL-12, TNF-α, IL-5, and IL-10 varied between groups and
according to evaluated tissue. A trend to the normalization of cytokine gene expression
was induced by both miltefosine and meglumine antimoniate combined therapies.
However, IFN-γ gene expression was still up-regulated in the three evaluated tissues.
Furthermore, the effect of treatment in the gene expression of cytokines that were not
significantly changed by infection, indicates that miltefosine and meglumine antimoniate
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combined therapy directly affects cytokine generation. Both combined therapies are
effective in CanL treatment, leading to sustained pro-inflammatory immune environments
that can compromise parasite survival and favor dogs’ clinical cure. In the current study,
anti-inflammatory and regulatory cytokines do not seem to play a prominent role in CanL
or during clinical recovery.
Keywords: canine leishmaniosis, peripheral blood mononuclear cells, lymph node, bone marrow, cytokine gene
expression, meglumine antimoniate, miltefosine, allopurinol
INTRODUCTION
Leishmaniosis constitute a group of parasitic diseases of
worldwide concern, that are considered by the World Health
Organization as neglected tropical diseases (1). Canine
leishmaniosis (CanL) caused by the intracellular protozoan
Leishmania infantum is a zoonotic disease endemic to several
southern European countries, including Portugal. In CanL, a
wide range of non-specific clinical signs can be present (2),
posing difficulties to a correct diagnosis. Previous studies
differentiated sick dogs into symptomatic, oligosymptomatic
and polysymptomatic (3–6) although more recently it has
been proposed an improved system to stage dog’s clinical
condition (7, 8). This classification system takes into account
the physical examination, clinicopathological abnormalities,
anti-Leishmania antibody titer, and the evaluation of renal
function according to the International Renal Interest Society
guidelines (9). Other proposals also consider a first stage of
exposed dogs as those living or that have lived in geographic
regions in which the presence of vectors has been confirmed
(10). CanL conventional treatments improve the dog’s clinical
condition, reducing skin parasite load and consequently
the risk of Leishmania transmission. Although it is not
definitively proved that treatment completely eliminates the
parasite (11), and relapses are common when therapy is
discontinued (3, 11, 12) it remains crucial to improve the
efficiency of protocols used for CanL treatment. The main
protocols for dog treatment usually include meglumine
antimoniate (N-methylglucamine antimoniate), miltefosine
(1-O-hexadecylphosphocholine), and allopurinol. Meglumine
antimoniate is a pentavalent antimonial-based drug whose
precise mechanism of action is not yet well-understood,
but being considered a multifactorial drug with probable
Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase;
BID, bis in die; BUN, Blood urea nitrogen; CanL, Canine leishmaniosis;
cDNA, Complementary DNA; CG, Control Group; CLWG, Canine
Leishmaniasis Working Group; CPDA-1, Citrate phosphate dextrose adenine;
CVBD, Canine vector-borne disease; DNA, Deoxyribonucleic acid; EDTA,
Ethylenediaminetetraacetic acid; IL, Interleukin; IFAT, Indirect Fluorescent
Antibody Test; IFN-γ, Interferon gamma; MCH, Mean corpuscular hemoglobin;
MCHC, Mean corpuscular hemoglobin concentration; MCV, Mean corpuscular
volume; MG+A, Meglumine antimoniate with Allopurinol; MPV, Mean
platelet volume; MT+A, Miltefosine with Allopurinol; PBMC, Peripheral
Blood Mononuclear Cell; PCA, Principal Component Analysis; PDW, Platelet
distribution width; qPCR, Real-time PCR; RDW, Red cell distribution width;
RNA, Ribonucleic acid; SID, semel in die; Th1, Type-1 T-Helper; Th2, Type-2
T-Helper; TGF-β, Transforming growth factor beta; TNF-α, Tumor necrosis
factor alpha; Treg, Regulatory T-cells; UPC, Urine Protein Creatinine ratio.
activity on parasite molecular processes, and influence in
macrophage microbicide activity (13, 14). Miltefosine is an
alkylphosphocholine compound able to induce apoptosis by
mechanisms still not entirely clear (15–18). Allopurinol is a
purine analog of adenosine nucleotide, which blocks RNA
synthesis, inhibiting Leishmania growth (19). Up to date,
meglumine antimoniate in combination with allopurinol is
considered the first line of treatment in Europe (2), while
miltefosine plus allopurinol has been the second line of
treatment. However, miltefosine therapy has been gaining more
attention (3–6), being recently authorized in 2017 for CanL
treatment in Brazil (20), a highly endemic country for both
canine and human leishmaniosis. Nevertheless, with the arising
of more reports of drug resistance that lead to either therapeutic
failure, unresponsiveness or relapse, whether it be in humans or
dogs, a deeper understanding of the usual therapies is imperative
(13, 15, 21, 22).
The immune response of dogs evidencing leishmaniosis
clinical signs has been usually characterized by higher levels
of specific antibodies, along with a type-2 T-helper (Th2)
response associated with the expression of interleukin (IL)-4,
IL-5, and IL-6 (23–25). On the contrary, protective immunity
is thought to be dependent on a strong type-1 T-helper
(Th1) response characterized by IL-2, IL-12, tumor necrosis
factor (TNF)-α, and interferon (IFN)-γ production (23, 25).
Furthermore, parasites may suppress host immunity by engaging
regulatory T-cells (Treg) thus enabling the persistence of the
infection (26), with one study showing clearance of Leishmania
infection after depletion of Treg populations in mice (27).
Moreover, higher expression of regulatory cytokines (IL-10,
tumor growth factor [TGF-β]) associated with high parasite
burden observed in dogs presenting clinical signs (28) suggest
a non-negligible role of these cytokines in disease progression.
To the best of our knowledge, there is no study defining the
ideal approach to CanL treatment based on the knowledge
of the immune response elicited by the different treatment
protocols, and there is only one study analyzing more than
one parasite target organ in non-treated CanL (29). Therefore,
further studies are essential to clarify how treatments affect
dogs’ ability to develop a protective immune response or,
on the contrary, to elicit immune suppression of effector
cells. In the present study, the influence of two different
treatment protocols on disease evolution of naturally infected
dogs and on immune response was evaluated by assessing the
clinicopathological changes, and the gene expression of pro-
inflammatory (IL-2, IL-12, TNF-α, IFN-γ), anti-inflammatory
(IL-4, IL-5) and regulatory (IL-10, TGF-β) cytokines in
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Twenty-three dogs with at least 1.5 years of age, weighing
more than 5 kg, not having been vaccinated for CanL and
diagnosed with CanL clinical stage I/II, according to the LeishVet
Consensus Guidelines (7), and stage C in agreement to the
Canine Leishmaniosis Working Group (CLWG) Guidelines
(10) were selected from a total of 170 household dogs
living in the zoonotic visceral leishmaniosis endemic area
of the Metropolitan Area of Lisbon (Portugal). Twelve of
those 23 dogs had not undergone any treatment in the last
8 months that could interfere with the immune response
(such as antibiotic and corticosteroid therapy or administration
of immunomodulators), and were negative for circulating
pathogens potentially responsible of canine vector-borne diseases
(CVBDs), were selected to participate in the current study.
Five clinical healthy dogs not having been vaccinated for CanL,
negative for Leishmania antibody test and CVBDs were also
included in the present study as a control group (Figure 1). All
dog owners gave written consent after being informed about the
objectives of the study and every procedure, ensuring that clinical
results were made available. Selected dogs include 13 males and
4 females of various breeds with ages ranging between 2 and
9 years and weight between 7.6 and 32.1 kg. Animal handling
and sample collection procedures were done by the Veterinary
team of the Teaching Hospital of the Faculty of Veterinary
Medicine, University of Lisbon (Lisbon, Portugal). The present
study followed the Council of the European Union Directive
86/609/EEC and was approved by the Ethics and Animal Welfare
Committee of the Faculty of Veterinary Medicine, University
of Lisbon.
Experimental Design
To reduce discomfort and ensure dog’s well-being, the amount
of sample collections and its periodicity were reduced to a
minimum. Blood, popliteal lymph node, and bone marrow
samples were collected from healthy (control group) and sick
dogs prior the onset of treatment (Tp0) and then from sick dogs,
1 (Tp1), 2 (Tp2), and 3 months (Tp3) after the beginning of
treatment. The samples collected from sick dogs at Tp0 were
used, not only, to establish the baseline levels of cytokine mRNA
accumulation, but also, for ethical reasons, to serve as controls
of themselves, avoiding the need of an extra group of sick
animals without any treatment. Treatment success was clinically
and serological re-assessed 6 months after the initial diagnosis
for each treated animal (Figure 2). Each dog was enrolled in
one of the two treatment protocols (Figure 1), according to the
following criteria:
(i) Dogs presenting increased blood urea nitrogen (BUN),
creatinine and/or alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and UCP between 0.2 and 0.6,
pointing to the possibility of developing hepatic and renal
lesion were treated with miltefosine (Milteforan R©, Virbac
S.A, France; 2 mg/kg per os, semel in die–SID–for 4 weeks) in
association with allopurinol (Zyloric R©, Laboratórios Vitória,
Portugal; 10 mg/kg, per os, bis in die–BID–for at least 6
months) (MT+A);
(ii) Dogs presenting changes in biochemical and hematological
parameters, serum proteins and UCP between 0.2 and 0.4
were treated with meglumine antimoniate (Glucantime R©,
Merial Portuguesa, Portugal; 100 mg/kg SID for 4 weeks) in
association with allopurinol 10 mg/kg, per os, BID for at least
6 months (MG+A).
Deltamethrin-impregnated collars were applied to all dogs to
prevent infections or re-infections during the current study and
also in order to avoid Leishmania dissemination to sand flies.
Blood samples were used for determination of hematological
and biochemical parameters, and serological and molecular
tests. Popliteal lymph node, bone marrow, and peripheral blood
were used to examine cytokine gene expression. Urine samples
were collected into sterilized containers for urinalysis and
determination of protein/creatinine ratio (UPC).
Sample Collection, Hematological and
Biochemical Analysis, and Serological
Tests
Peripheral blood (20ml) was collected into syringes containing
citrate phosphate dextrose adenine (CPDA-1, Medinfar
Sorológico, Portugal). Popliteal lymph node aspirates were
collected into syringes containing 0.8ml of saline solution
(0.9% NaCl) in order to avoid cell disruption and were then
transferred to ethylenediaminetetraacetic acid (EDTA) tubes to
avoid coagulation. After cutaneous anesthesia with a Xylocaine
10% Pump Spray (AstraZeneca, UK), bone marrow aspirates
were collected from the distal area of the costal ribs, between
the 9th and the 11th, into syringes containing 0.8ml of saline
solution. An additional 4ml of blood was collected in EDTA
tubes and dry tubes to be used for hematological (complete blood
count), biochemical analysis (serum measurement of alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
alkaline phosphatase, bilirubin, blood urea nitrogen (BUN),
creatinine, inorganic phosphorus, calcium, sodium, potassium,
chlorides), serum proteinogram electrophoresis, and CVBD
screening. Peripheral blood samples were also used for the
isolation of mononuclear cells. Popliteal lymph node and bone
marrow were used for detection of Leishmania amastigote forms
and isolation of mononuclear cells.
Leishmania Screening
Serum samples were used for detection of anti-Leishmania
antibodies by IFAT assay (Leishmania-Spot IF, BioMérieux,
France) using L. infantum promastigotes as antigen and following
the manufacturer’s instructions. Samples were screened using
an Olympus DP10 microscope (model BX50F, wavelength of
425 nm) and classified as positive if fluorescence was observed
in promastigote cytoplasm or membrane at a serum dilution
of 1:80 or higher. According to LeishVet (7) and the Canine
Leishmaniosis Working Group (CLWG) guidelines (10), IFAT
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FIGURE 1 | Flowchart representing the dog’s selection process used in the current study. From a total of 170 dogs, living in an endemic area of zoonotic visceral
leishmaniosis, two groups of dogs with canine leishmaniosis (CanL) were constituted, and were treated with either miltefosine in combination with allopurinol (MT+A)
or with meglumine antimoniate in association with allopurinol (MG+A) along with one group of clinically healthy dogs (Control Group–CG). These dogs were negative
for Canine Vector-Borne Diseases (CVBD). ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BUN, Blood urea nitrogen.
is a gold standard test for canine leishmaniosis and to evaluate
possible relapses.
To test for the presence of Leishmania DNA, total genomic
DNA was extracted from 200 µl of peripheral blood using
the DNeasy R© Blood and Tissue kit (QIAGEN R©, Germany)
according to the manufacturer’s instructions. DNA amplification
by qPCR was done in a total volume of 20 µl, comprising
10 µl of TaqMan R© Gene Expression Master Mix (Applied
BiosystemsTM, USA), 2µl of ultra-pure water (MerckMilliporeTM
KGaA, Germany), 300 nM of forward and reverse primers
for each set as well as 250 nM for each probe (Table 1) and
2 µl of target DNA. Reactions were carried out using the
7300 Real-Time PCR thermal cycler (Applied BiosystemsTM),
with the following cycling conditions: 10min at 95◦C for
AmpliTaq R© Gold activation, followed by a total of 40 cycles
of 15 s at 95◦C and 1min at 60◦C. The positive control
was constructed by cloning PCR fragments generated by
the same primers into a pGEM R©-T Easy Vector (Promega,
USA), according to the manufacturer’s instructions. Ligated
fragments were transformed into JM109 competent cells and
plasmid DNA was prepared using the QIAprep R© Spin Miniprep
Kit (QIAGEN R©). The insert was sequenced using primers
pUC/M13 (Promega) to ensure transformation stability. To
exclude the presence of Leishmania amastigotes, lymph node
and bone marrow slides were stained with Giemsa and observed
by optical microscopy (Microscope Olympus CX31, using a
1,000×magnification).
CVBD Exclusion
Detection of antibodies against Babesia, Anaplasma, Ehrlichia,
and Rickettsia was performed using commercial diagnostic
tests (Megacor R© MegaScreen, Austria, FLUOBABESIA canis–
cut off 1:32; FLUOANAPLASMA phagocytophilum–cut off
1:50; FLUOEHRLICHIA canis–cut off 1:50; FLUORICKETTSIA
conorii–cut off 1:40). The absence of Babesia, Anaplasma,
Ehrlichia, and Rickettsia DNA was also evaluated by qPCR
(Table 1) as previously described. To exclude the presence of
Dirofilaria immitis microfilaria, blood samples were evaluated
by Knott technique and parasite antigens were assessed by
Witness R© Dirofilaria kit (Zoetis, Portugal) according to the
manufacturer’s instructions.
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FIGURE 2 | Clinical manifestations of a dog naturally infected with Leishmania infantum. (A,B) Dog presenting evident loss of weight, lethargy, cutaneous alopecia,
and exfoliative dermatitis; (C) Ulcerative and hyperkeratosis lesions in the elbow of the front limb; (D) Onychogryphosis with severe bleeding; (E) Dog from the MT+A
group 6 months after the diagnosis with full remission of clinical signs. Photos by Marcos Santos.
TABLE 1 | Primers and TaqMan probes used for hemoparasite screening.
Target Oligo Oligonucleotide sequence (5′ → 3′) Product size (bp) References
Leishmania (Kinetoplast) Frw GGAAGGTGTCGTAAATTCTGGAA 124 (30)
Rev CGGGATTTCTGCACCCATT
Probea AATTCCAAACTTTTCTGGTCCTCCGGGTAG
Ehrlichia and Anaplasma (16S rRNA) Frw ACCTATAGAAGAAGTCCCGGCAA 100 (31)
Rev ACCTACGTGCCCTTTACGCCC
Probea GCAGCCGCGGTAATACGGAGGGGGC
Babesia (18S rRNA) Frw ACCCATCAGCTTGACGGTAGGGT 97 (32)
Rev AGCCGTCTCTCAGGCTCCCT
Probeb ACCGAGGCAGCAACGGGTAACGGGGA
Rickettsia (OmpA) Frw AACCGCAGCGATAATGCTGAGTAGT 130 (33)
Rev CCCTGCAGAAGTTATCTCATTCCAA
Probeb AGCGGGGCACTCGGTGTTGCTGCA
Presence of parasites in dog blood was evaluated by qPCR. Product base pair (bp) for each pathogen and primer references are also indicated. Frw, forward primer; Rev, reverse primer.
aProbe labeled with 6-FAM at the 5′-end and quenched with TAMRA at the 3′-end. bProbe labeled with JOE at the 5′-end and quenched with TAMRA at the 3′-end.
Cell Isolation
Dog peripheral blood was re-suspended in PBS (1:1 v/v),
overlaid onto a 1:2 Histopaque R©-1077 solution (Sigma-Aldrich,
Germany) and centrifuged at 400 g for 30min at 18◦C.
Mononuclear cells were harvested and washed in cold PBS (300
g, 10min, 4◦C), re-suspended in PBS, and the total volume
adjusted to 2 × 107 cells ml−1. Lymph node and bone marrow
aspirates were centrifuged at 400 g (4◦C) for 5 and 15min,
respectively, and re-suspended in 100 µl, with the total volume
also adjusted for 2 × 107 cells.ml−1. Then, 200 µl of peripheral
bloodmononuclear cells (PBMCs) and 100µl of lymph node and
bone marrow cell suspensions were centrifuged at 400 g (4◦C)
for 5min, re-suspended in 600 µl of RLT Buffer (QIAGEN R©)
supplemented with β-mercaptoethanol and stored at−80◦C until
further use.
mRNA Extraction and Reverse
Transcription
Total RNA extracted from PBMCs, lymph node, and bone
marrow cells, using RNeasy R© Mini Kit (QIAGEN R©) and
QIAshredder R© spin columns (QIAGEN R©) was treated with
DNase I Amplification Grade (InvitrogenTM, USA) according
to the manufacturer’s instructions. For cDNA synthesis, 1
µg of purified RNA, presenting a 260/280 absorbance ratio
ranging between 1.9 and 2.1 was denatured at 65◦C for 5min
and reverse transcribed at 37◦C for 60min in a 30 µl final
reaction mixture containing 6 µl of 5× M-MLV RT Buffer
(Promega), 200 U/µl SCRIPT Reverse Transcriptase enzyme
(Jena Bioscience, Germany), 500µl dNTPMix (Jena Bioscience),
1 µl of Oligo(dT)18 primers (Thermo Fisher Scientific Inc.TM,
EU), and 40 U/µl RiboLock RNase Inhibitor (Thermo Fisher
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TABLE 2 | Primers used for quantification of cytokine mRNA expression by qPCR.
Target Oligo Oligonucleotide sequence (5′→ 3′) Product size (bp) References
IL-2 Frw GCATCGCACTGACGCTTGTA 86 (34)
Rev TTGCTCCATCTGTTGCTCTGTT
IL-4 Frw CATCCTCACAGCGAGAAACG 83 (35)
Rev CCTTATCGCTTGTGTTCTTTGGA
IL-5 Frw GCCTATGTTTCTGCCTTTGC 106 (36)
Rev GGTTCCCATCGCCTATCA
IL-10 Frw CAAGCCCTGTCGGAGATGAT 78 (37)
Rev CTTGATGTCTGGGTCGTGGTT
IL-12p40 Frw CAGCAGAGAGGGTCAGAGTGG 109 (34)
Rev ACGACCTCGATGGGTAGGC
TNF-α Frw AATCATCTTCTCGAACCCCAAGT 74 (38)
Rev GGAGCTGCCCCTCAGCTT
TGF-β Frw CAGAATGGCTGTCCTTTGATGTC 79 (35)
Rev AGGCGAAAGCCCTCGACTT
IFN-γ Frw TCAACCCCTTCTCGCCACT 113 (36)
Rev GCTGCCTACTTGGTCCCTGA
β-actin Frw ACGGAGCGTGGCTACAGC 62 (38)
Rev TCCTTGATGTCACGCACGA
bp, base pair; Frw, forward primer; Rev, reverse primer.
Scientific Inc.TM). cDNA samples were then heated at 95◦C
for 10min for enzyme inactivation and stored at −20◦C until
further use.
Cytokine Gene Expression
To evaluate the effect of treatment in pro-inflammatory, anti-
inflammatory, and regulatory cytokines, the accumulation of
mRNA encoding for IL-2, IL-4, IL-5, IL-10, IL-12, TNF-
α, TGF-β, and IFN-γ was assessed by qPCR in PBMC,
lymph node and bone marrow cell. cDNA amplification was
conducted in a 20 µl final reaction mixture containing 10 µl
of SYBR R© Green PCR Master Mix (Applied BiosystemsTM),
80 nM of forward and reverse primers for each cytokine
and for housekeeping gene β-actin (Table 2), 4 µl of ultra-
pure water (Merck MilliporeTM KGaA) and 2 µl of canine
cDNA. Each sample amplification was performed in triplicate,
using the following conditions: 10min at 95◦C for AmpliTaq R©
Gold activation followed by a total of 40 cycles (thermal
profile for each cycle: 15 s at 95◦C, 1min at 60◦C). An
extra dissociation step was added to confirm the specificity
of amplification by melting point analysis, and absence of
non-specific products. External cDNA standards for all target
cytokines and internal control used in every reaction were
constructed as previously described. The concentration of
standards was determined by measuring the OD at 260 nm
followed by calculation of the corresponding copy number,
and serial dilutions of resulting clones were used as standard
curves, each containing a known amount of input copy number
(39, 40). Copy numbers of target genes were normalized to
the housekeeping gene β-actin, therefore correcting for minor
variations in mRNA isolation and reverse transcription. Final
results were expressed as the copy number of each cytokine per
1,000 copies of the housekeeping gene. Amplification efficiencies
were >90%.
Data Analysis
An exploratory multivariate statistical analysis, specifically the
Principal Component Analysis (PCA), was performed per tissue,
on all datasets, in order to identify principal components
accounting for the majority of the variation and graphically
assess the separation between the healthy control, sick (Tp0) and
treated dogs (Tp1, Tp2 and Tp3). This statistical analysis was
performed using JMP version 14.3.0 (SAS Institute). Likewise,
a K-Means Cluster analysis was also used to complement
the previous PCA analysis and confirm grouping separation.
In order to reduce the number of irrelevant or redundant
variables and present a more robust model, a feature selection
method was employed. Using the Predictor Screening tool
from JMP the individual contribution of each variable was
obtained, and the selected features were considered in the
final models.
Statistical analysis between treatment groups was performed
using GraphPad Prism software package version 8.0.1. Data
normality was assessed using the Kolmogorov-Smirnoff test.
Wilcoxon signed rank test was used to compare hematological
and biochemical results in each dog treatment group between
Tp0 and Tp3, with differences being considered significant
when p < 0.05. The non-parametric Kruskal-Wallis Test (one-
way ANOVA on ranks) with Dunn’s post hoc test was used
to evaluate differences in mRNA levels between treatment
groups and the CG. The Repeated Measures ANOVA Test
with Tukey’s post hoc test was used to compare dogs at
different time-points.







































TABLE 3 | Hemogram values exhibited by dogs of MT+A and MG+A groups.




Tp0 Tp1 Tp2 Tp3 Tp0 Tp1 Tp2 Tp3
RBC (×106/µl) 5.49 ± 1.32 5.30 ± 1.85 5.71 ± 1.07 5.87 ± 0.91 – 5.22 ± 0.55 5.54 ± 1.18 6.36 ± 0.65 6.82 ± 0.68 * 7.21 ± 1.05 5.5–8.5
Hemoglobin (g/dl) 12.32 ± 2.95 11.83 ± 3.55 13.08 ± 2.50 12.66 ± 3.24 – 11.24 ± 2.15 12.33 ± 2.59 14.25 ± 1.73 15.50 ± 1.26 * 16.26 ± 2.41 12–8
Hematocrit (%) 37.85 ± 10.89 35.45 ± 12.20 38.98 ± 7.60 37.44 ± 9.51 – 34.80 ± 6.09 37.38 ± 9.93 42.45 ± 5.86 45.27 ± 3.63 * 51.40 ± 7.29 37–55
MCV (µm3 ) 68.48 ± 4.13 67.15 ± 2.95 68.24 ± 2.80 68.72 ± 2.13 – 66.38 ± 7.04 67.12 ± 9.17 66.63 ± 4.71 66.53 ± 3.46 – 71.40 ± 1.69 60–74
MCH (pg) 22.60 ± 1.53 22.67 ± 1.35 22.92 ± 0.89 23.26 ± 0.54 – 21.02 ± 1.94 22.30 ± 1.48 22.42 ± 1.07 22.75 ± 1.25 – 22.54 ± 0.65 19.5–24.5
MCHC (g/dl) 33.10 ± 2.95 33.83 ± 2.65 33.70 ± 2.42 33.84 ± 0.78 – 32.32 ± 1.60 33.60 ± 3.51 33.72 ± 1.49 34.22 ± 1.28 – 31.62 ± 1.63 31–36
RDW (%) 13.16 ± 0.94 13.78 ± 0.95 13.88 ± 1.09 13.46 ± 1.44 – 13.43 ± 0.99 14.45 ± 2.35 13.08 ± 1.07 13.00 ± 0.97 – 12.34 ± 0.54 12–18
Leukocytes (×103/µl) 8.17 ± 2.98 7.83 ± 2.38 9.22 ± 2.13 7.76 ± 3.82 – 7.50 ± 2.47 8.62 ± 3.83 9.03 ± 2.90 9.55 ± 3.42 – 10.24 ± 3.18 6–17
Lymphocytes (×103/µl) 1.67 ± 0.51 2.23 ± 0.86 3.18 ± 1.64 2.96 ± 2.29 – 1.56 ± 0.85 2.12 ± 1.11 2.37 ± 0.81 2.22 ± 0.87 – 2.80 ± 0.70 1–4.8
Monocytes (×103/µl) 0.66 ± 0.25 0.48 ± 0.19 0.48 ± 0.22 0.40 ± 0.23 – 0.68 ± 0.24 0.67 ± 0.50 0.50 ± 0.26 0.47 ± 0.23 – 0.48 ± 0.20 0.2–2
Neutrophils (×103/µl) 5.60 ± 2.27 4.38 ± 1.35 4.92 ± 1.41 3.86 ± 1.45 – 5.11 ± 1.45 5.40 ± 2.71 5.77 ± 2.40 6.43 ± 2.95 – 5.96 ± 2.14 3–11.8
Eosinophils (×103/µl) 0.27 ± 0.28 0.70 ± 0.57 0.58 ± 0.40 0.52 ± 0.64 – 0.14 ± 0.21 0.42 ± 0.23 0.35 ± 0.19 0.38 ± 0.21 * 0.98 ± 0.40 0.1–1.3
Basophils (×103/µl) 0.02 ± 0.04 0.03 ± 0.05 0.04 ± 0.05 0.00 ± 0.00 – 0.02 ± 0.04 0.03 ± 0.05 0.07 ± 0.08 0.03 ± 0.05 – 0.06 ± 0.05 0–0.5
Platelets (×103/µl) 280.67 ± 133.4 233.83 ± 130.8 254.00 ± 150.8 235.00 ± 43.62 – 212.80 ± 133.5 246.50 ± 125.1 227.17 ± 60.38 222.50 ± 58.32 – 217 ± 25.84 200–500
MPV (µm3 ) 11.82 ± 2.94 12.82 ± 2.88 11.14 ± 2.27 11.82 ± 2.28 – 14.73 ± 3.14 11.82 ± 2.70 11.33 ± 2.56 10.73 ± 1.82 – 10.38 ± 1.28 5–15
Procalcitonin (%) 0.30 ± 0.14 0.28 ± 0.10 0.26 ± 0.13 0.26 ± 0.09 – 0.28 ± 0.15 0.23 ± 0.15 0.27 ± 0.08 0.25 ± 0.10 – 0.22 ± 0.04 0.2–0.5
PDW (%) 65.04 ± 11.24 64.33 ± 9.75 66.12 ± 11.74 64.62 ± 10.11 – 74.08 ± 3.95 57.98 ± 21.28 70.58 ± 8.48 73.87 ± 5.91 – 59.06 ± 5.03 40.6–65.2
At diagnosis time (Tp0), and 1 (Tp1), 2 (Tp2) and 3 (Tp3) months after the beginning of the treatment. Blood samples of sick (n = 12) and healthy dogs (control group [CG], n = 5) were used to evaluate hemogram parameters. Reference
values are also included. Wilcoxon signed rank text was used to compare between Tp0 and Tp3 in each treatment group.
*p < 0.05. MCH, Mean Corpuscular Hemoglobin; MCHC, Mean Corpuscular Hemoglobin Concentration; MCV, Mean Corpuscular Volume; MPV, Mean Platelet Volume; PDW, Platelet Distribution Width; RBC, Red Blood Cells; RDW,


























































































TABLE 4 | Biochemical parameters and urinalysis results exhibited by dogs of MT+A and MG+A groups.




Tp0 Tp1 Tp2 Tp3 Tp0 Tp1 Tp2 Tp3
BUN (mg/dl) 60.35 ± 22.86 45.27 ± 35.79 33.23 ± 8.49 25.25 ± 7.04 * 26.03 ± 5.09 31.92 ± 3.84 34.50 ± 7.11 34.60 ± 6.82 * 36.33 ± 3.64 15-40
Creatinine (mg/dl) 1.20 ± 0.88 1.08 ± 0.68 1.19 ± 1.04 0.88 ± 0.62 – 0.55 ± 0.08 0.64 ± 0.12 0.87 ± 0.26 0.82 ± 0.27 – 0.92 ± 0.24 0.4-1.4
Total bilirubin (mg/dl) 0.05 ± 0.02 0.05 ± 0.01 0.06 ± 0.02 0.06 ± 0.04 – 0.04 ± 0.00 0.04 ± 0.00 0.05 ± 0.02 0.04 ± 0.00 – 0.06 ± 0.02 0.04-0.4
Direct bilirubin (mg/dl) 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.02 0.02 ± 0.01 – 0.02 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 – 0.04 ± 0.01 0-0.3
Indirect bilirubin (mg/dl) 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.04 ± 0.04 – 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 – 0.02 ± 0.02 0-0.3
AST (U/l) 62.80 ± 29.48 45.83 ± 12.12 46.17 ± 11.74 42.60 ± 17.62 – 49.25 ± 2.87 42.40 ± 13.79 58.50 ± 9.07 37.83 ± 17.36 – 40 ± 4.19 10-40
ALT (U/l) 93.83 ± 76.94 86.00 ± 42.70 78.33 ± 42.16 65.20 ± 40.53 – 44.17 ± 36.34 29.33 ± 16.19 30.33 ± 11.71 37.67 ± 16.11 – 40.25 ± 7.46 10-70
Alkaline phosphatase (U/l) 146.1 ± 166.4 131.78 ± 161.7 146.48 ± 243.8 30.05 ± 15.95 * 49.18 ± 15.34 38.95 ± 13.42 35.30 ± 7.10 35.28 ± 12.70 * 41.45 ± 29.56 20-200
Sodium (mmol/l) 145.60 ± 4.67 148.50 ± 8.76 146.50 ± 3.02 143.60 ± 3.21 – 142.25 ± 4.86 146.67 ± 2.34 146.67 ± 2.42 148.50 ± 3.56 – 146.75 ± 2.22 140-151
Potassium (mmol/l) 4.86 ± 0.79 4.70 ± 0.89 4.68 ± 0.49 4.54 ± 0.44 – 4.62 ± 0.34 4.59 ± 0.39 4.50 ± 0.27 4.40 ± 0.26 – 5.07 ± 0.53 3.4-5.4
Chloride (mmol/l) 112.80 ± 1.92 102.67 ± 13.94 113.50 ± 4.93 92.78 ± 51.56 – 108.00 ± 4.08 108.17 ± 9.35 104.17 ± 7.17 111.67 ± 6.02 – 113.00 ± 6.48 105-120
Calcium (mg/dl) 9.99 ± 0.51 9.54 ± 0.35 9.48 ± 0.72 9.08 ± 0.93 – 9.92 ± 0.42 9.93 ± 0.30 9.89 ± 0.32 10.14 ± 0.36 – 9.50 ± 1.57 9.5-12
Inorganic phosphorus (mg/dl) 4.96 ± 0.68 5.90 ± 2.87 4.35 ± 1.60 3.58 ± 0.92 – 3.95 ± 0.59 3.73 ± 0.67 3.35 ± 1.03 3.58 ± 1.25 – 4.60 ± 0.79 2.1-5
Biliary acids (µmol/l) 3.07 ± 2.11 3.22 ± 2.94 3.18 ± 3.34 3.36 ± 2.83 – 1.40 ± 0.25 3.54 ± 3.44 2.19 ± 1.28 1.72 ± 1.11 – 2.47 ± 1.34 1-10
Urinalysis
Creatinine (mg/dl) <1.4 <1.4 <1.4 <1.4 – <1.4 <1.4 <1.4 <1.4 – < 1.4 < 1.4
UPC <0.2–0.6 <0.2–0.5 <0.2 <0.2 – <0.2–0.4 <0.2–0.4 <0.2 <0.2 – < 0.2 < 0.2
At diagnosis time (Tp0), and 1 (Tp1), 2 (Tp2), and 3 (Tp3) months after the beginning of the treatment. Blood and urine samples of sick (n=12) and healthy dogs [control group (CG), n = 5] were used to evaluate biochemical parameters
and urinalysis. Reference values are also included. Wilcoxon signed rank text was used to compare between Tp0 and Tp3 in each dog group.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Both Treatment Protocols Lead to Dog’s
Clinical Remission
Blood smears of dogs from MT+A, MG+A, and Control
Group were all negative for CVBD causing agents. The dogs
presented negative serology for Babesia, Anaplasma, Ehrlichia,
and Rickettsia, and were negative for DNA detection of
these parasites. Dogs were also negative in rapid immune
migration for D. immitis antigen and microfilaria were absent in
Knott technique.
Clinical signs observed in sick dogs at the beginning of
the study (Tp0) included loss of body weight (Figures 2A,B),
local/generalized lymphadenopathy, decreased/increased
appetite, lethargy, mucousmembrane pallor, polyuria/polydipsia,
cutaneous alopecia, onychogryphosis (Figure 2D),
hyperkeratosis, exfoliative-dermatitis, and erosive-ulcerative
dermatitis (Figure 2C). Other clinical signs, such as epistaxis,
lameness, and masticatory muscle myositis were also observed.
No clinical signs were detected in dogs of the Control Group.
Sick dogs showed also changes in hematological and biochemical
parameters, including a mild decrease of hemoglobin values,
mild erythropenia, lower hematocrit values, thrombocytopenia
(Table 3), mild renal azotemia (Table 4), hyperglobulinemia with
increased alpha 2 and gamma globulin fractions, and decreased
values of alpha 1 and albumin/globulin ratio (Table 5, Figure 3).
Dogs of group MT+A presented higher BUN values and an
accentuated AST and ALT while dogs of the MG+A group
exhibited BUN normal values and a slight increase in ALT and
AST values (Table 4, Figure 3). Three dogs of group MT+A
also showed creatinine values inferior to 1.4 mg/dL and mild
proteinuria, presenting a urine protein:creatinine ratio (UPC)
of 0.6. Control group dogs exhibited normal hematological
and biochemical parameters, serum proteins, and urinalysis
values. Lymph node and bone marrow smears of dogs from
both MT+A and MG+A groups presented amastigote forms
inside macrophages associated with lymphoid hyperplasia.
Dogs from both groups showed anti-Leishmania antibody titers
ranging between 1:80 and 1:320. No antileishmanial antibodies
were detected in dogs from the Control Group (Table 6).
One month after treatment (Tp1) dogs of MG+A exhibited
higher vivacity and energy than dogs from MT+A. Three
months after treatment onset (Tp3), both groups exhibited
a successful recovery, showing remission of all clinical signs.
Dogs from the MT+A group presented a significant recovery
(p < 0.05) of BUN values to normal levels. AST and ALT
quickly recovered to normal values in dogs of group MG+A
(Table 4). Although presenting higher AST and ALT values,
combined treatment of miltefosine and allopurinol promoted
the decrease of AST and ALT in dogs from the MT+A group,
albeit slower, with urinalysis values returning to normal. Dogs
in MG+A group exhibited a normalization of the albumin
globulin ratio 2 months after the beginning of treatment (Tp2)
and 1 month later (Tp3) total protein and gamma globulin
were within reference values. However, in dogs of the MT+A
group the total protein and gamma globulin remained high
and alpha 2 globulin normalized 3 months after the beginning
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FIGURE 3 | Serum protein electrophoresis of sick and treated dogs. Representative proteinograms of sick [Tp0; (A) MT+A; (B) MG+A], treated [Tp3; (C) MT+A; (D)
MG+A] and clinically healthy dogs (E) are shown. Alb, Albumin; α1, α1-globulin; α2, α2-globulin; β, β-globulin; γ, γ-globulin.
of the treatment (Tp3) (Table 5, Figure 3). Three months
after treatment onset (Tp3), MG+A dogs were negative for
anti-Leishmania antibodies and, with the exception of one
dog that had a titer of 1:320 group MT+A dogs were also
negative. When re-evaluated 6 months after the initial diagnosis
this positive dog was negative for antileishmanial antibodies
(Table 6). Furthermore, amastigote forms were no longer
observed in lymph node and bone marrow smears of dogs from
both groups.
Principal Component and Cluster Analysis
Enable the Distinction Between Healthy
and Sick Dogs
Principal component analysis in PBMCs confirmed that healthy
and sick dogs could be distinguished based on their expression
of IFN-γ, IL-2, IL-4, IL-5, IL-12, and TGF-β along with IFAT
results, with these features explaining 65.5% of the distribution
(Figure 4A). In lymph node, PCA was also able to distinguish
healthy and sick dogs based on the expression of IFN-γ,
IL-2, and IL-10 along with IFAT results, with 63.4% of the
distribution being explained by these variables (Figure 4C). For
bone marrow the expression of IFN-γ, IL-4, IL-5, and IL-
12 along with IFAT results, enabled the distinction between
healthy and sick dogs, with these features explaining 72.3% of
the distribution (Figure 4E). These results are also supported
by cluster analysis (Figures 4B,D,F), with the formation of two
separate groups. Dogs from both treatment groups could not be
distinguished based on the selected features, but the transition
from the sick dogs cluster toward the healthy dog cluster along
the time-points can be observed in PBMC, lymph node, and
bone marrow.
TABLE 6 | Anti-Leishmania antibody titers.
Leishmania
antibody titer
Tp0 Tp1 Tp2 Tp3 Tp6
Group 1
(n = 6)
1:80–1:320 <1:80–1:320 <1:80–1:160 <1:80 <1:80
Group 2
(n = 6)
1:80–1:320 <1:80–1:320 ≤1:80 <1:80–1:320 <1:80
Control group
(n = 5)
<1:80 <1:80 <1:80 <1:80 <1:80
At diagnosis time (Tp0), and 1 (Tp1), 2 (Tp2), 3 (Tp3), and 6 (Tp6) months after the
beginning of treatment, peripheral blood of sick (n = 12) and control dogs [control group
(CG), n= 5] were collected and used to evaluated anti-Leishmania antibody titers by IFAT.
A cut-off of 1:80 was used.
Leishmania Infection Shapes Dogs’
Cytokine Profile
Sick dogs (MT+A and MG+A) showed a significant
accumulation of IFN-γ mRNA in cells of PBMC (pMT+A =
0.0057; pMG+A = 0.0425; Figure 5J), lymph node (pMT+A =
0.001; pMG+A = 0.0028; Figure 5K), and bone marrow (pMT+A
= 0.0097; pMG+A = 0.0267; Figure 5L) when compared with
clinically healthy dogs (CG). Bone marrow cells of dogs of
MT+A showed a significant upregulation of IL-12 (p = 0.0059;
Figure 5F) in comparison to control dogs. On the other hand,
lymph node cells of sick dogs evidenced a significant reduction
in IL-2 mRNA (pMT+A = 0.0365; pMG+A = 0.0068; Figure 5B).
Dogs of MG+A group also showed a significant downregulation
of IL-2 gene expression in PBMC (p = 0.0193; Figure 5A) and
TNF-α in lymph node cells (p = 0.0186; Figure 5H). While dogs
of MT+A group showed a significant upregulation of TNF-α
gene expression in bone marrow cells (p = 0.0413; Figure 5I).
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No significant differences were found in gene expression of IL-12
by PBMC and lymph node cells, IL-2 by bone marrow cells and
TNF-α by PBMC when compared to clinically healthy dogs.
PBMC (pMT+A = 0.0662; pMG+A = 0.0032; Figure 6A)
and bone marrow (pMG+A = 0.0138; Figure 6C) of sick dogs
evidenced a significant down regulation of IL-4 gene expression
in comparison to the CG. In lymph node cells, no significant
differences were observed in the IL-4 gene expression. PBMC of
sick dogs from MT+A group (p = 0.0031; Figure 6D) and bone
marrow cells of dogs of group MG+A (p = 0.0082; Figure 6F)
showed a statistically significant downregulation of IL-5 gene
expression. Additionally, lymph node cells of MT+A showed a
significant accumulation of IL-5 mRNA (p= 0.0235; Figure 6E).
A significant IL-10 downregulation in PBMC of MG+A (p =
0.0153; Figure 7A) and an upregulation in lymph node cells of
sick dogs (pMT+A = 0.0041, pMG+A = 0.0112; Figure 7B). No
significant differences in IL-10 gene expression were observed in
bonemarrow cells of sick dogs when comparedwith control dogs.
A significant reduction in the accumulation of TGF-β mRNA
was observed in PBMC (pMG+A = 0.0112; Figure 7D) and
lymph node cells (pMT+A = 0.0425; pMG+A = 0.0057; Figure 7E)
of sick dogs in relation to the CG. Bone marrow cells of
MG+A group (Figure 7F) also showed a significant TGF-β
downregulation (p= 0.0186).
Although there were differences between sick dogs, these
results seem to indicate that Leishmania infection can shape the
dogs’ immune response by inducing IFN-γ upregulation while
others pro-inflammatory (IL-2), anti-inflammatory (IL-4) and
regulatory (TGF-β) cytokines were downregulated. Additionally,
the modulation of TNF-α, a key player in macrophage activation,
IL-5, which is involved in the differentiation of activated B
lymphocytes into Ig-secreting plasma cells, and IL-10, a cytokine
associated with immune regulation, seems to be tissue specific.
Increased Gene Expression of
Pro-inflammatory Cytokines Persists After
Treatment With Miltefosine in Combination
With Allopurinol
Gene expression of cytokines that were modified by infection
was further evaluated along all time-points and studied tissues.
In dogs treated with MT+A, bone marrow (Figure 5F) cells
evidenced an IL-12 gene expression similar to CG 1 month
after the beginning of treatment and throughout the study,
pointing toward normalization. IFN-γ gene expression was still
up-regulated in PBMC (pTp1 = 0.0027, pTp2 = 0.0023, pTp3 =
0.0013; Figure 5J), lymph node (pTp2 = 0.0061; Figure 5K) and
bone marrow (pTp1 = 0.0057, pTp2 = 0.0061, pTp3 = 0.0047;
Figure 5L) cells during the observation period. In lymph node
cells, there was a slight increase in IFN-γ mRNA accumulation
at Tp2 when compared to Tp1 (pTp1 = 0.0032). Nevertheless, a
tendency to normalization was observed in bone marrow.
A significant high amount of IL-2 mRNA was found in
lymph node cells at Tp3 (p = 0.0143) when compared to the
CG (Figure 5B). In bone marrow cells, TNF-α gene expression
persisted elevated (pTp1 = 0.0303, pTp3 = 0.0481) throughout all
time-points (Figure 5I).
FIGURE 4 | Principal Component and Cluster Analysis of cytokine expression
in PBMC, lymph node and bone marrow. Principal component analysis was
used to identify the first two principal components which explain 65.5, 63.4,
and 72.3% for each respective tissue, of the variation in the dataset. (A,C,E)
Biplot of score and loading plots showing the variables which load on the
respective principal components. Control, MG+A, and MT+A groups are
presented by different colored dots along all time-points, with the control
group and the sick dogs (Tp0) delimited by their respective halo. Colored
arrows show the transition of treated dogs over time. (B,D,F) Cluster analysis
confirming the separation of healthy and sick dogs (Tp0) using the selected
variables. PC, Principal Component.
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FIGURE 5 | Pro-inflammatory cytokine gene expression in dogs treated with either MT+A or MG+A protocol along all time-points. IL-2 (A–C), IL-12 (D–F), TNF-α
(G–I), and IFN-γ (J–L) mRNA in PBMC (A,D,G,J), lymph node (B,E,H,K) and bone marrow (C,F,I,L) cells of dogs from MT+A, MG+A, and Control Group (CG) was
evaluated by qPCR. Results of 17 dogs and three replicates per sample are represented by box and whisker plot, median, minimum, and maximum values. The
non-parametric Kruskal-Wallis Test (one-way ANOVA on ranks) with Dunn’s post hoc test was used for statistical comparisons between treatments groups and the
CG. The Repeated Measures ANOVA Test with Tukey’s post hoc test was used for statistical comparisons inside each treatment group. *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001) indicate statistical significance.
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FIGURE 6 | Anti-inflammatory cytokine gene expression in dogs treated with either MT+A or MG+A protocol along all time-points. IL-4 (A–C) and IL-5 (D–F) mRNA
in PBMC (A,D), lymph node (B,E), and bone marrow (C,F) cells of dogs from MT+A, MG+A, and Control Group (CG) was evaluated by qPCR. Results of 17 dogs
and three replicates per sample are represented by box and whisker plot, median, minimum, and maximum values. The non-parametric Kruskal-Wallis Test (one-way
ANOVA on ranks) with Dunn’s post hoc test was used for statistical comparisons between treatments groups and the CG. The Repeated Measures ANOVA Test with
Tukey’s post hoc test was used for statistical comparisons inside each treatment group. *p < 0.05, **p < 0.01 indicate statistical significance. Ø shows mRNA
expression values of only three dogs.
In PBMC, IL-4 gene expression recovered by Tp2 when
compared with CG (Figure 6A), while in bone marrow a low
accumulation of IL-4 mRNA (Figure 6C) was observed (pTp1 =
0.0365, pTp2 = 0.0420) throughout the study. Even so, at TP3
there was a slight upregulation of IL-4 gene expression, revealing
a tendency to revert to normal values. Although a fluctuation of
IL-5 gene expression was observed (Figure 6D), at Tp3 it reverts
to values compared with CG. In lymph node cells, although IL-5
gene expression maintained increased at Tp1 (Figure 6E) when
compared with CG (p = 0.0124), at Tp3 a trend to reduction in
IL-5 mRNA accumulation points toward normalization.
IL-10 and TGF-β gene expression revealed a tendency
to recuperation to normal values. Namely, IL-10 mRNA
accumulation in lymph node (Figure 7B) was significantly
decreased when compared to Tp0 (pTp1 = 0.0338, pTp2 = 0.0144,
pTp3 = 0.0409), along with a significant increase of TGF-βmRNA
accumulation in PBMC (p < 0.0001) at Tp3 (Figure 7D) similar
to CG and in lymph node at Tp2 (p = 0.0112) when compared
with Tp0 (Figure 7E).
Despite the generalized tendency of treated dogs to achieve
normal levels, the upregulation of pro-inflammatory cytokines
(IFN-γ and IL-2) together with the trend to the normalization
of anti-inflammatory (IL-4 and IL-5) and regulatory cytokines
(IL-10 and TGF-β) point toward a persistent inflammatory
immune response during the 3 months of treatment.
Upregulation of IFN-γ Gene Expression
Persists After Treatment With Meglumine
Antimoniate Combined Therapy
Dogs treated with MG+A evidenced a normalization of IFN-
γ gene expression in PBMC (Figure 5J). IFN-γ gene expression
remained significantly higher (pTp1 = 0.0029, pTp3 = 0.0018)
in lymph node cells in comparison to CG (Figure 5K). On the
contrary, bone marrow cells (Figure 5L) showed a progressive
decrease of IFN-γ mRNA. At Tp1 (p = 0.0425) the values were
significantly increased when compared to the CG. However,
by Tp2 and Tp3, IFN-γ gene expression lowered toward levels
comparable to the CG. On the other hand, IL-2 (Figure 5B) and
TNF-α (Figure 5H) gene expression in lymph node cells was
similar to the CG. IL-2 at Tp1 in PBMC (Figure 5A) presented
values similar to control dogs, with Tp3 having significant
difference to Tp0 (p = 0.0425). The same was verified in lymph
node, with IL-2 recovering to amounts comparable to CG by
Tp3 (p = 0.0098). TNF-α (Figure 5H) in lymph node recovered
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FIGURE 7 | Regulatory cytokine gene expression in dogs treated with either MT+A or MG+A protocol along all time-points. IL-10 (A–C) and TGF-β (D–F) mRNA in
PBMC (A,D), lymph node (B,E), and bone marrow (C,F) cells of dogs from MT+A, MG+A, and Control Group (CG) was evaluated by qPCR. Results of 17 dogs and
three replicates per sample are represented by box and whisker plot, median, minimum, and maximum values. The non-parametric Kruskal-Wallis Test (one-way
ANOVA on ranks) with Dunn’s post hoc test was used for statistical comparisons between treatments groups and the CG. The Repeated Measures ANOVA Test with
Tukey’s post hoc test was used for statistical comparisons inside each treatment group. *p < 0.05, **p < 0.01, and ****p < 0.0001 indicate statistical significance.
to values similar to CG showing a significant difference when
compared to Tp0 (p= 0.0451).
During treatment follow-up, IL-4 gene expression remained
downregulated in PBMC (pTp1 = 0.0219, pTp2 = 0.0297)
(Figure 6A) and in bone marrow cells (pTp1 = 0.0068, pTp2 =
0.0229, pTp3 = 0.0013; Figure 6C) when compared with the CG.
In PBMC, IL-5 gene expression was also downregulated (pTp1 =
0.0199, pTp2 = 0.0071, pTp3 = 0.0343; Figure 6D). Despite a slight
reduction in the accumulation of IL-5 mRNA in bone at Tp2, it
was noticed a tendency to normalization (Figure 6F).
During treatment, accumulation of IL-10 (pTp1 = 0.0076,
pTp2 = 0.0101, pTp3 = 0.0108; Figure 7A) and TGF-β (pTp1 =
0.0192, pTp2 = 0.0235, pTp3 = 0.0473; Figure 7D) mRNA was
highly reduced in PBMC when compared to the CG. However,
in lymph node cells, IL-10 (Figure 7B) and TGF-β (Figure 7E)
gene expression was similar to control dogs. Nonetheless, at Tp3,
a slight increase of TGF-β mRNA in lymph node was observed
when compared to Tp2 (p = 0.0285). Despite bone marrow cells
showed a normalization of TGF-β gene expression (Figure 7F),
2 months after treatment (Tp3) a significant decrease of TGF-
β mRNA accumulation (p = 0.0453) was observed when
compared to healthy dogs. Leishmania infected dogs treated
with meglumine antimoniate in combination with allopurinol
(MG+A) evidence a generalized tendency to achieve normal
cytokine levels in the Leishmania host tissues evaluated in the
current study. However, the persistent upregulation of IFN-γ
gene expression associated with downregulation of IL-4, IL-
5, IL-10, and TGF-β gene expression indicates the possible
predominance of an inflammatory immune response. On the
other hand, the slight increase of TGF-β at Tp3 in the lymph
node can point toward the local activation of a regulatory
immune response.
The Activity of Miltefosine and Meglumine
Antimoniate Combined Therapies Can
Influence Cytokine Gene Expression
To estimate the influence of the drugs in cytokine generation,
the cytokines that were not significantly altered by Leishmania
infection were analyzed by comparing gene expression of sick
(Tp0) and treated dogs (Tp1-Tp3).
After the first month of treatment (Tp1) with miltefosine
in association with allopurinol (MT+A), PBMC evidenced a
downregulation of IL-12 (p = 0.0025; Figure 5D) and IL-10
(Figure 7A), and a slight upregulation of IL-2 (Figure 5A) and
TNF-α (Figure 5G). During the second and third month IL-2,
TNF-α, and IL-10 showed a progressive upregulation, with IL-12
having an accentuated increase at Tp2 (p = 0.0411) and a slight
decrease by Tp3 (p= 0.0233). Regarding lymph node cells, it was
observed a considerable upregulation of IL-12 (Figure 5E) after
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Tp1 (p = 0.0062), along with a slight overexpression of TNF-
α (Figure 5H) at Tp2 and Tp3 (p = 0.0138) time-points and a
considerable gene expression of IL-4 (Figure 6B) at Tp1 followed
by downregulation by Tp2 and Tp3 (p = 0.0410). In bone
marrow, the treatment caused accumulation of IL-2 (Figure 5C)
mRNA that persisted until Tp2, along with an increase of TGF-β
(Figure 7F) that peaked at Tp3 (p = 0.0106). IL-5 (Figure 6F)
mRNA levels showed a downregulation by Tp1 (p = 0.0343)
that persisted until Tp2. A progressive downregulation of IL-10
(Figure 7C) was evident from Tp1 to Tp3 (p= 0.0452).
PBMC of dogs treated with MG+A showed a progressive
downregulation of IL-12 (Figure 5D) from Tp0 to Tp2, followed
by an increase at Tp3, and a progressive TNF-α (Figure 5G)
increase from Tp0 that reached maximum values by Tp3.
Lymph node cells presented IL-12 (Figure 5E) mRNA levels
increased by Tp3 (p = 0.0484), exhibiting a slight and transitory
downregulation of IL-4 (Figure 6B) levels at Tp1 (p = 0.0293)
followed by a progressive upregulation that peaked at Tp3. IL-
5 (Figure 6E) was slightly downregulated at Tp1 but showed
an accentuate increase when meglumine antimoniate was
discontinued (Tp2), with a slight decrease by Tp3 (p = 0.0344).
Regarding bone marrow cells, a continuous decrease in IL-12
and TNF-α mRNA accumulation was noticed from Tp1 to Tp3.
However, IL-2 gene expression presented an irregular pattern,
suffering a downregulation at Tp2. When compared with Tp0,
IL-10 presented a progressive downregulation until Tp3.
These findings indicate thatMG+Adirects the overexpression
of cytokines in blood and lymph node and is possible that
allopurinol plays a key role in enhancing cytokine generation.
In the bone marrow, the drugs seem to downregulate
cytokine gene expression. MT+A also seems to enhance
cytokine gene expression. However, when miltefosine was
discontinued, IL-4 in lymph node and IL-10 in the bone marrow
became downregulated.
DISCUSSION
Progression of L. infantum infection is mainly dependent
on the competence of the dog’s immune system, which is
related to inherent characteristics such as genetic background.
Thus, the spectrum of clinical manifestations can range from
subclinical infection to severe disease. During active disease, dog’s
immune response has been mainly characterized by a marked
humoral immune response and specific immunosuppression of T
lymphocyte proliferation (41). Despite being the major domestic
reservoir of L. infantum, dogs have also intrinsic value, more
notably a recognized social and affective role. Therefore, the
use of therapies that can ensure a successful CanL treatment is
highly required.
Several studies have pointed out the efficacy and faster
recovery rate of dogs treated with meglumine antimoniate in
combination with allopurinol (5, 19, 42, 43). Regarding the
progress of hematological, biochemical, and urinary parameters,
it is worth to emphasize that both combined therapies used
in the current study were able to recover erythrocytes,
hemoglobin, hematocrit, and UCP normal values, while
leukocytes, neutrophils, creatinine, and albumin were within
the reference intervals during the 3 months of treatment. Dogs
evidencing less clinicopathological alterations, that were selected
to be treated with meglumine antimoniate in combination
with allopurinol, presented a fast recovery of hematological,
biochemical and urinary parameters. Dogs showing more
clinicopathological alterations, and which were treated with
miltefosine in combination with allopurinol, took longer to
reach normalization of those parameters.
Three months after CanL diagnosis (Tp3), both combined
therapies were successful in promoting remission of clinical
signs, recovering of hematological and biochemical normal
values in all dogs and in restraining parasite infection
since amastigotes were not found in the bone marrow and
lymph node smears. Anti-parasite antibodies also diminished
to non-significant titers in most of the dogs, with only
one dog treated with MG+A taking more time to become
negative (>3 months).
During CanL, L. infantum parasites are hosted in several
organs of the reticuloendothelial system, having a widespread
influence on the host’s immune system. As previously reported
(28, 39, 44), in CanL, IFN-γ gene expression is increased in
parasite-host tissue prior to any treatment. Also in the current
study PBMC, lymph node and bone marrow cells evidenced
a pronounced generation of IFN-γ. Although such immune
response is widely verified in many other studies, it also raised
the question if this Th1 immune response is positively correlated
with parasite control. Previous studies in experimentally infected
hamsters and in humans suffering from visceral leishmaniosis
have shown high parasite loads in Th1 environments, indicating
an IFN-γ inability to confer protection (45, 46). Thus, the main
consensus indicates that sick dogs express high levels of IFN-γ
in Leishmania-target tissues, possibly directing a Th1 immune
response against persistent infection.
The most studied tissue regarding cytokine expression during
CanL is the peripheral blood, which in animals presenting
clinical signs is characterized as having suppression of T cell
mediated immunity and production of high levels of specific
antibodies (24), as a consequence of a predominantly Th2
response with production of anti-inflammatory cytokines, such
as IL-4 and IL-5 (23). In the present study, with the exception
of high IFN-γ gene expression, peripheral blood IL-2, TGF-β,
IL-4, and IL-5 of non-treated dogs were decreased, suggesting
that Leishmania caused an overall lymphocyte deactivation,
leading to unbalance of pro- and anti-inflammatory immune
mediators. Still, taking into consideration that the peripheral
blood is not the tissue of election for L. infantum replication and
persistence (47, 48), along with possible natural genetic variability
between dogs, it may be the reason why there is so much
divergence between studies regarding cytokine expression in
this tissue.
Despite most of CanL studies being focused in only one tissue,
usually the peripheral blood, more and more studies consider
that every single tissue affected by this parasite presents its own
immune response (28, 39, 49, 50). IL-10 is a key regulatory
cytokine that prevents excessive pathology. This cytokine can
negatively regulate innate and adaptive immune responses by
impairing the production of pro-inflammatory (e.g., IL-12, IL-2,
IFN-γ, and TNF-α) and anti-inflammatory (IL-4 and IL-5)
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cytokines, restraining T cell activity in lymph nodes and limiting
tissue inflammation. In CanL, the lymph node is reported as
having a predominantly Th1 immune response (39). Besides this,
a true consensus has not been established, with studies showing
higher expression of Th1 cytokines, like IFN-γ and TNF-α (51),
in pre-scapular lymph nodes of dogs without external clinical
signs and lower parasite burden, pointing toward a possible role
of these cytokines in controlling parasite replication. In contrast,
dogs presenting clinical signs showed no expression of IL-4 and
IL-12, but high levels of immunosuppressor cytokines like IL-
10 and TGF-β (51), posing a role in disease progression. In
the current study, the lymph node of dogs with CanL seems
to evidence a mixed Th1/Treg immune response with low IL-
2, but high IL-12 and IFN-γ, along with down expression of
TGF-β but over expression of IL-10, pointing toward a balance
between the differentiation of IFN-γ mediated inflammatory
response and a regulatory immune response that could favor
parasite persistence.
Considering the cytokine expression in bone marrow of
dogs with CanL, to our best knowledge, there are only a
few documented studies (28, 39, 44), which report this tissue
as a predominantly Th1 environment that tends to develop
high parasite loads, characterized by an increased expression
of IFN-γ and TNF-α and low to no detection of IL-10,
along with lower expression of IL-4 (28, 44). In the current
study, bone marrow cells of sick dogs also evidence IFN-γ
overexpression and low expression of IL-4, IL-5, and TGF-
β pointing to a predominantly pro-inflammatory immune
response. Furthermore, the PCA and cluster analysis reinforce
that each tissue presents a distinct cytokine pattern of response
to infection, confirming previous reports (39). Furthermore,
infection level also seems to influence local cytokine gene
expression, namely TNF-α, that points toward a diminished
generation of this cytokine in lymph node cells of dogs presenting
less clinicopathological signs (MG+A), and overexpression in
bone marrow cells of dogs with severe clinicopathological signs
(MT+A). TNF-α together with IFN-γ induce the upregulation of
inducible nitric oxide synthase (iNOS) bymacrophages, directing
L-arginine oxidation and nitric oxide (NO) production (52).
NO is a powerful oxidative molecule that mediates parasite
killing. Thus, the hypothesis that TNF-α can be a biomarker
of CanL severity needs to be further investigated. Furthermore,
IL-5, a cytokine linked to growth and differentiation of B
cells, evidenced to be over-expressed in lymph node cells of
dogs presenting more clinicopathological signs (MT+A). These
findings point to a higher B cell activation in lymph node.
The over expression of IL-12 in bone marrow cells of dogs
exhibiting more clinicopathological signs (MT+A), a signaling
pathway cytokine that prime naïve T cells to differentiate
into Th1 cells, supports the possible establishment of a Th1
cell population.
By analyzing the peripheral blood, popliteal lymph node
and bone marrow along the course of two of the most
used CanL protocol treatments, the current study shows
evidence of a higher IFN-γ generation during the 3 months
of follow up of dogs treated with MT+A. Furthermore,
lymph node cells also exhibited a TNF-α overexpression,
suggesting that there are conditions for macrophage activation
and parasite inactivation, and increased generation of IL-2,
indicating a possible lymphocyte proliferation. These findings
indicate that miltefosine associated therapy does not promote
reduction of pro-inflammatory immune response, but, induces
the normalization of anti-inflammatory IL-4 and IL-5 and
of immune-suppresor TGF-β in mononuclear blood cells, of
immune-suppressor IL-10 in lymph node and of IL-5, TGF-β and
pro-inflammatory IL-12 in bone marrow.
MG+A lead to the normalization of the proinflammatory
immune response, restoring IFN-γ and IL-2 expression levels in
blood cells, IL-2, IL-12, and TNF-α in lymph node and IFN-γ in
the bone marrow. Although showing some instability, IL-5 tends
to normal values in the bone marrow. Treatment also seems to
induce the normalization of immunosuppressor cytokines in the
lymph node. However, the continuous overexpression of IFN-γ
in lymph node cells points toward the maintenance of a local
inflammatory response despite the drug activity in promoting the
remission of clinical signs, and the rise of IFN-γ gene expression
in mononuclear blood cells 1 month post-treatment suggests the
predomination of a Th1 immune response. On the other hand,
IL-4 and IL-5 stay downregulated in mononuclear blood cells as
well as IL-10 and TGF-β indicating the inhibition of Th2 and Treg
immune response even during dogs’ clinical improvement. In
bone marrow as well, treatment did not induce the normalization
of IL-4 gene expression.
The effect of drug therapies used in the current study in
cytokine gene expression was investigated in the cytokines
that were not significantly affected by parasite infection (Tp0).
Although combined therapies seem to have similar outcomes,
it was not possible to find a distinctive pattern, exhibiting
cytokine, and tissue dependent effects. The drug activity possibly
empowered by free parasite antigens seems to favor mainly
cytokine generation.
The current study enables a close overview of the effect
of the two most used anti-leishmanial therapies, miltefosine,
and meglumine antimoniate in association with allopurinol, in
reversing CanL progression on naturally infected dogs, including
clinical signs remission, normalization of hematological,
biochemical and urinary parameters, and IFAT seroconversion.
Both combined therapies are effective in CanL treatment,
favoring clinical recovery of all dogs and the overexpression of
pro-inflammatory cytokines, pointing toward the persistence of
inflammatory immune environments that can direct parasite
inactivation at least during the initial 3 months of treatment.
The current study also demonstrates that anti-inflammatory and
regulatory cytokines do not seem to play a key role in CanL
immune response. Furthermore, the combined therapies also
appear to play a direct role in cytokine generation. These are
relevant findings, since both are two of the most used protocols
in the treatment of this zoonotic parasitosis, the evolution of
the cell-mediated immune response generated while under these
specific treatments should be further studied. With the recent
implementation of miltefosine for CanL treatment in Brazil, an
extremely endemic country for canine and human leishmaniosis,
it becomes a subject of ensuring the best for the reinforcement of
Public Health protection.
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